EN DE
Watch Theriva Biologics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Theriva Biologics Inc. (TOVX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Theriva Biologics Inc. stock $0.14, price $0.15, that is 10.6% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TB Theriva Biologics Inc. logo Thin data Nov 10, 2026

Theriva Biologics Inc.

TOVX · US
Expensive, weak quality

Our calculation puts a fair price 11% below what the stock costs today.

Low debt
Costs just 0.2 times its yearly profit.
Mixed Growth (revenue YoY +2969.7 %/yr in USD)
Fair value $0.1378 · Overvalued
Quality 36/100
Negative free cash flow
Trails peers (3/8)
Narrow moat 9/100
Thin data
Estimate
Watch Theriva Biologics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$130.00 $0.1542 Fair Value $0.1378 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.1542 – $130.00 · fair‑value band $0.1033 – $0.1722 · the $0.1542 price screens above the $0.1378 fair value. As of Nov 10, 2026.

Follow Theriva Biologics in your weekly email

Every Wednesday you see whether Theriva Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States.

Show moreShow less

Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.

The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.

In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics.

The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.

Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Stock analysis

Theriva Biologics Inc. (TOVX) currently trades at $0.1542, while our estimate is $0.1378, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.1033 (bear) to $0.1722 (bull), the price of $0.1542 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Theriva Biologics Inc. reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$25.2M in FY2025.

Key figures

Market cap $8.6M Micro · P/E ratio 0.2 · P/S ratio 28.6 · EPS (TTM) $0.7300 · Return on equity −102% · Return on assets (EBIT) −40.6% (5-year average) · Operating margin −4,022% · Revenue (TTM) $300K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −11%, TOVX screens richer than that median.

Fair Value

Bear $0.1033 Fair Value $0.1378 Bull $0.1722
Price $0.1542 · Downside -10.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2,969.7%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,400.0% (1993) → −50.1% (2010)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TOVX screens overvalued: fair value 11% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Theriva Biologics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −10.6% · Top 25%
Profitability
Return on assets −66.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 0.2× · Cheapest 25%
P/B 0.56× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 28.61× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs TOVX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs TOVX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs TOVX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs TOVX
argenx SE ARGX $971.55 $908.40 −7% vs TOVX
CSL Limited CSL A$201.68 A$181.40 −10% vs TOVX
Moderna, Inc MRNA $250.83 $158.70 −37% vs TOVX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs TOVX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs TOVX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs TOVX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Theriva Biologics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Theriva Biologics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/TOVX

Frequently asked questions

Is Theriva Biologics Inc. (TOVX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.1378 versus a price of $0.1542, about 11% lower (overvalued).
What is the fair value of TOVX?
Our estimate for Theriva Biologics Inc. is $0.1378 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.1542.
What is the quality score of TOVX?
Theriva Biologics Inc. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Theriva Biologics Inc. (TOVX)?
Our calculated price target is the estimate of $0.1378 (as of Nov 10, 2026). Cautious scenario $0.1033, optimistic scenario $0.1722. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Theriva Biologics Inc. stock forecast for 2026?
Our estimate puts fair value at $0.1378, about 11% lower versus a price of $0.1542 (overvalued). Cautious scenario $0.1033, optimistic scenario $0.1722. The calculation is refreshed regularly with new filings.
What is the revenue of Theriva Biologics Inc. (TOVX)?
Theriva Biologics Inc. reported trailing-twelve-month revenue of about $300K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Theriva Biologics Inc. (TOVX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Theriva Biologics Inc. it is $0.1378 per share (as of Nov 10, 2026), against a price of $0.1542.
Is Theriva Biologics Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, TOVX trades above its calculated fair value: price $0.1542, fair value $0.1378, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TOVX?
No. The price is what the market pays today ($0.1542); the fair value is what the company's own numbers justify ($0.1378). For Theriva Biologics Inc. the two are $0.0164 per share apart. That gap is exactly why we show both numbers side by side.
How much is Theriva Biologics Inc. worth?
The market values Theriva Biologics Inc. at about $8.6M (market capitalisation, as of Nov 10, 2026). Per share that is $0.1542; our models calculate a fair value of $0.1378 per share.
What do the bullish and bearish scenarios say about TOVX?
Our models span a range for Theriva Biologics Inc.: cautious scenario $0.1033, base $0.1378, optimistic $0.1722 per share (as of Nov 10, 2026, price $0.1542). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TOVX?
Theriva Biologics Inc. trades at a price-to-earnings ratio of 0.2 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1378 is built from several models across several years. Other multiples: P/B 0.6, P/S 28.6.
How solid is the balance sheet of Theriva Biologics Inc. (TOVX)?
Balance-sheet figures for Theriva Biologics Inc. (as of Nov 10, 2026): return on equity −101.9%, debt of 0.11 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is TOVX from its 52-week high?
Theriva Biologics Inc. trades at $0.1542, about 62% below its 52-week high of $0.4100 and at the low of $0.1542 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1378 is for.
Which stocks are comparable to Theriva Biologics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Theriva Biologics Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $0.1542, calculated fair value $0.1378 (−11%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Theriva Biologics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Theriva Biologics Inc. (TOVX)?
The closing price on Nov 10, 2026 was $0.1542. Our estimate is $0.1378, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Theriva Biologics Inc. right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Theriva Biologics Inc.

How large is the market capitalisation of Theriva Biologics Inc. (TOVX)?
The market capitalisation of Theriva Biologics Inc. is $8.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Theriva Biologics Inc. (TOVX)?
The price-to-sales ratio of Theriva Biologics Inc. is 28.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Theriva Biologics Inc. (TOVX)?
Earnings per share at Theriva Biologics Inc. are $0.7300 (price ÷ EPS = P/E 0.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Theriva Biologics Inc. (TOVX)?
The return on equity (ROE) of Theriva Biologics Inc. is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Theriva Biologics Inc. (TOVX)?
On an EBIT basis the return on assets of Theriva Biologics Inc. is −40.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Theriva Biologics Inc. (TOVX)?
The operating margin of Theriva Biologics Inc. is −4,022% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Theriva Biologics Inc. (TOVX) generate?
The free cash flow of Theriva Biologics Inc. is −$16.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Theriva Biologics Inc. (TOVX) hold?
Theriva Biologics Inc. holds more cash than debt, $10.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Theriva Biologics Inc. in the live analysis

One click puts Theriva Biologics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.